4164-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2016-N-0001]

Food and Drug Administration Clinical Trial Requirements, Regulations, Compliance, and Good

Clinical Practices; Public Workshop

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of public workshop.

SUMMARY: The Food and Drug Administration (FDA) is announcing the following public workshop entitled "Educational Conference Co-Sponsored With the Society of Clinical Research Associates (SOCRA)." The public workshop on FDA's clinical trial requirements is designed to aid the Clinical Research Professional's understanding of the mission, responsibilities, and authority of FDA and to facilitate interaction with FDA representatives. The program will focus on the relationships among FDA, clinical trial staff, investigators, and institutional review boards (IRBs). Individual FDA representatives will discuss the informed consent process and informed consent documents; regulations relating to drugs, devices, and biologics; as well as inspections of clinical investigators, of IRBs, and of research sponsors.

DATES: The public workshop will be held on March 9 and 10, 2016, from 8 a.m. to 5 p.m. ADDRESSES: The public workshop will be held at the Holiday Inn San Diego Bayside, 4875 North Harbor Dr., San Diego, CA 92106, 619-224-3621.

FOR FURTHER INFORMATION CONTACT: Jane Kreis, Food and Drug Administration, 1301 Clay St., suite 1180N, Oakland, CA 94612, 510-287-2708, FAX: 510-287-2739, or Society of Clinical Research Associates (SOCRA), 530 West Butler Ave., suite 109, Chalfont,

PA 18914, telephone: 800-762-7292 or 215-822-8644, FAX: 215-822-8633, Office@socra.org, Web site: www.socra.org. (FDA has verified the Web site addresses throughout this document, but we are not responsible for any subsequent changes to the Web sites after this document publishes in the Federal Register.)

SUPPLEMENTARY INFORMATION:

I. Background

The public workshop helps fulfill the Department of Health and Human Services' and FDA's important mission to protect the public health. The workshop will provide those engaged in FDA-regulated (human) clinical trials with information on a number of topics concerning FDA requirements related to informed consent, clinical investigation requirements, IRB inspections, electronic record requirements, and investigator initiated research.

FDA has made education of the drug and device manufacturing community a high priority to help ensure the quality of FDA-regulated drugs and devices. The workshop helps to achieve objectives set forth in section 406 of the FDA Modernization Act of 1997 (21 U.S.C. 393), which include working closely with stakeholders and maximizing the availability and clarity of information to stakeholders and the public. The workshop also is consistent with the Small Business Regulatory Enforcement Fairness Act of 1996 (Pub. L. 104-121), as outreach activities by Government Agencies to small businesses.

II. Topics for Discussion at the Public Workshop

Topics for discussion include the following: (1) The Role of the FDA District Office Relative to the Bioresearch Monitoring Program (BIMO); (2) Modernizing FDA's Clinical Trials/BIMO; (3) What FDA Expects in a Pharmaceutical Clinical Trial; (4) Medical Device Aspects of Clinical Research; (5) Adverse Event Reporting--Science, Regulation, Error, and

Safety; (6) Working With FDA's Center for Biologics Evaluation and Research; (7) Ethical Issues in Subject Enrollment; (8) Keeping Informed and Working Together; (9) FDA Conduct of Clinical Investigator Inspections; (10) Investigator Initiated Research; (11) Meetings With FDA--Why, When, and How; (12) Part 11 Compliance--Electronic Signatures; (13) IRB Regulations and FDA Inspections; (14) Informed Consent Regulations; (15) The Inspection is Over--What Happens Next? Possible FDA Compliance Actions; and (16) Question and Answer Session/Panel Discussion.

Registration: The registration fee will cover actual expenses including refreshments, lunch, materials, and speaker expenses. Seats are limited; please submit your registration as soon as possible. Workshop space will be filled in order of receipt of registration. Those accepted into the workshop will receive confirmation. The cost of the registration is as follows: SOCRA member--\$575, SOCRA nonmember (includes membership)--\$650, Federal Government member--\$450, Federal Government nonmember--\$525, and FDA Employee--(free) Fee Waived.

Attendees are responsible for their own accommodations. Please mention SOCRA to receive the hotel room rate of \$142 plus applicable taxes (available until the SOCRA room block is filled).

If you need special accommodations due to a disability, please contact SOCRA (see FOR FURTHER INFORMATION CONTACT) at least 21 days in advance.

Extended periods of question and answer and discussion have been included in the program schedule. SOCRA designates this education activity for a maximum of 13.3 Continuing Education (CE) Credits for SOCRA CE and Nurse CNE; SOCRA designates this live activity for a maximum of 13.3 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit

4

commensurate with the extent of their participation. CME for Physicians: SOCRA is accredited

by the Accreditation Council for Continuing Medical Education to provide continuing medical

education for physicians. CNE for Nurses: Society of Clinical Research Associates is accredited

as a provider of continuing nursing education by the American Nurses Credentialing Center's

Commission on Accreditation.

Registration Instructions: To register, please submit a registration form with your name,

affiliation, mailing address, telephone, fax number, and email, along with a check or money

order payable to "SOCRA." Mail to: SOCRA(see FOR FURTHER INFORMATION

CONTACT). To register via the Internet, go to http://www.socra.org/html/FDAConference.htm.

Payment by major credit card is accepted (Visa/MasterCard/AMEX only). For more information

on the meeting registration, or for questions on the workshop, contact SOCRA (see FOR

FURTHER INFORMATION CONTACT).

Dated: February 9, 2016.

Leslie Kux,

Associate Commissioner for Policy.

[FR Doc. 2016-02965 Filed: 2/12/2016 8:45 am; Publication Date: 2/16/2016]